UTP is not a biased agonist at human P2Y11 receptors

Purinergic Signalling

Volumn 10, Issue 4, 2014, Pages 581-585

  Morrow, Gael B ^a   Nicholas, Robert A ^b   Kennedy, Charles ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Biased agonism; Inositol phosphates; Intracellular Ca2+; P2Y11 receptor

Indexed keywords

CALCIUM; P2RY11 PROTEIN, HUMAN; PURINERGIC P2 RECEPTOR; URIDINE TRIPHOSPHATE;

ASTROCYTOMA; HUMAN; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ASTROCYTOMA; CALCIUM; CELL LINE, TUMOR; HUMANS; RECEPTORS, PURINERGIC P2; SIGNAL TRANSDUCTION; URIDINE TRIPHOSPHATE;

EID: 84930838452     PISSN: 15739538     EISSN: 15739546     Source Type: Journal    
DOI: 10.1007/s11302-014-9418-3     Document Type: Article

References (16)

1. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1–13
2. o G proteins: evidence for agonist regulation of G protein selectivity. Br J Pharmacol 138:775–786
3. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP (1998) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54:94–104
4. Liu JJ, Horst R, Katritch V, Stevens RC, Wüthrich K (2012) Biased signaling pathways in β2-adrenergic receptor characterized by 19 F-NMR. Science 335:1106–1110
5. Rahmeh R, Damian M, Cottet M, Orcel H, Mendre C, Durroux T, Sharma KS, Durand G, Pucci B, Trinquet E, Zwier JM, Deupi X, Bron P, Banères JL, Mouillac B, Granier S (2012) Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy. Proc Natl Acad Sci U S A 109:6733–6738
6. 15 receptor is not a genuine P2Y receptor. Trends Pharmacol Sci 26:8–9
7. Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Fumagalli M, Gachet C, Jacobson KA, Weisman GA (2006) International Union of Pharmacology. Update of the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev 58:281–341
8. Kennedy C, Chootip K, Mitchell C, Syed NH, Tengah A (2013) P2X and P2Y nucleotide receptors as targets in cardiovascular disease. Future Med Chem 5:431–439
9. Hoffmann C, Ziegler N, Reiner S, Krasel C, Lohse MJ (2008) Agonist-selective, receptor-specific interaction of human P2Y receptors with β-arrestin-1 and -2. J Biol Chem 283:30933–30941
10. 11 receptors: evidence for agonist-specific signalling. Mol Pharmacol 63:1356–1363
11. 11 receptor to phospholipase C and adenylyl cyclase. Br J Pharmacol 132:318–326
12. Nicholas RA, Watt WC, Lazarowski ER, Li Q, Harden K (1996) Uridine nucleotide selectivity of three phospholipase C-activating P2 receptors: identification of a UDP-selective, a UTP-selective, and an ATP- and UTP-specific receptor. Mol Pharmacol 50:224–229
13. Lazarowski ER, Watt WC, Stutts JM, Boucher RC, Harden TK (1995) Pharmacological selectivity of the cloned human P2U-purinoceptor: potent activation by diadenosine tetraphosphate. Br J Pharmacol 116:1619–1627
14. Communi D, Govaerts C, Parmentier M, Boeynaems J-M (1997) Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase. J Biol Chem 272:31969–31973
15. 11 receptor. Br J Pharmacol 128:1199–1206
16. 4 receptor. Mol Pharmacol 57:926–931